Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

This study has been completed.
Sponsor:
Collaborators:
SAIC-Frederick, Inc.
Therapeutics for Rare and Neglected Diseases (TRND)
QS Pharma
National Chung Cheng University
Infrared Imaging and Thermometry Unit, Biomedical Engineering and Physical Science Shared Resource (NIBIB)
ClinPharm Consulting, LLC
Ricerca Biosciences LLC
National Heart, Lung, and Blood Institute (NHLBI)
Cato Research
Information provided by (Responsible Party):
Baxalta US Inc.
ClinicalTrials.gov Identifier:
NCT01597401
First received: April 26, 2012
Last updated: August 6, 2015
Last verified: August 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2013
  Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)